Tue, November 24, 2009
Mon, November 23, 2009
Sun, November 22, 2009
Fri, November 20, 2009
Thu, November 19, 2009
Wed, November 18, 2009
Tue, November 17, 2009
Mon, November 16, 2009
Sun, November 15, 2009
Fri, November 13, 2009
Thu, November 12, 2009
Wed, November 11, 2009
Tue, November 10, 2009
Mon, November 9, 2009
Fri, November 6, 2009
Thu, November 5, 2009
Wed, November 4, 2009
Tue, November 3, 2009
Mon, November 2, 2009
Sun, November 1, 2009
Fri, October 30, 2009
Thu, October 29, 2009
Wed, October 28, 2009
Tue, October 27, 2009
Mon, October 26, 2009
Sun, October 25, 2009
Fri, October 23, 2009
Thu, October 22, 2009
Wed, October 21, 2009
Tue, October 20, 2009
Mon, October 19, 2009
Fri, October 16, 2009
Thu, October 15, 2009
Wed, October 14, 2009

IMRIS reports record third quarter results


//health-fitness.news-articles.net/content/2009/ .. /imris-reports-record-third-quarter-results.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


[ CNW Group ]
[ Home | ][ Products & Services ] | [ Social Media Releases ] | [ About Us ] | [ Contact Us ][ Client Login ] | [ Français ]

[ ] >[ TELL A FRIEND ] >[ PRINTER FRIENDLY ] >[ SUBSCRIBE TO PORTFOLIO E-MAIL ]

[ Save to del.icio.us ] [ Submit to Digg ] [ Seed Newsvine ] [ Find blogs discussing this release ]

IMRIS INC.
[ Detailed Chart... ]

IMRIS reports record third quarter results

WINNIPEG, Nov. 2 /CNW/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today reported third quarter 2009 financial results highlighted by record sales, and gross profit performance.

 Highlights: - Sales increased 103% to $9.9 million over Q3 2008 - Gross profit as a percentage of sales increased to 45% compared with 27% in Q3 2008 - Order bookings of $10.6 million contributed to 73% year over year growth in backlog - IMRISNV and IMRIScardio approved for sale in the US and Canada 
 Financial Highlights: ------------------------------------------------------------------------- 3 months ended Sept. 30 9 months ended Sept. 30 ---------------------------------------------------------- ($ 000's except per share amounts) (unaudited) 2009 2008 Change 2009 2008 Change ------------------------------------------------------------------------- Sales 9,864 4,869 103% 24,496 17,219 42% ------------------------------------------------------------------------- Gross profit 4,462 1,327 236% 10,739 3,187 237% ------------------------------------------------------------------------- Gross profit as % of sales 45.2% 27.3% - 43.8% 18.5% - ------------------------------------------------------------------------- Operating expenses 6,078 6,356 (4%) 18,663 17,159 9% ------------------------------------------------------------------------- Operating loss before the following (1,616) (5,029) (68%) (7,924) (13,972) (43%) ------------------------------------------------------------------------- Foreign exchange (loss) gain (1,034) 231 - (1,658) 238 - ------------------------------------------------------------------------- Interest income (6) 118 - (1) 586 - ------------------------------------------------------------------------- Net loss (2,656) (4,680) (43%) (9,583) (13,148) (27%) ------------------------------------------------------------------------- Basic & diluted loss per share (0.10) (0.17) (41%) (0.35) (0.48) (27%) ------------------------------------------------------------------------- Cash, cash equivalents & accounts receivable 12,441(1) 19,806(2) (37%) 12,441(1) 19,806(2) (37%) ------------------------------------------------------------------------- Total assets 36,364(1) 39,849(2) (9%) 36,364(1) 39,849(2) (9%) ------------------------------------------------------------------------- Third Quarter and Nine Month Results Sales ----- 
 Gross Profit ------------ 
 Operating Expenses ------------------ 
 Operating Loss and Net Loss --------------------------- 
 Liquidity and Capital Resources ------------------------------- 
 Order Backlog ------------- 
 IMRISNV and IMRIScardio ----------------------- 
 -------------------- (1) Excludes net proceeds of approximately $19.3 million from the issuance of 3,697,250 common shares of the Company pursuant to an offering that closed on November 2, 2009. (2) At December 31. 

Publication Contributing Sources